## A New Era in HIV Prevention: Long-Acting Lenacapavir Offers Hope
More than forty years have passed since the initial identification of HIV, and despite significant advancements in managing the virus with pharmaceutical interventions, a preventative vaccine remains elusive. However, recent research published in 2024 indicates a promising alternative: a twice-yearly injectable antiviral medication demonstrating efficacy comparable to a vaccine in preventing HIV infection.
### The Science Behind Lenacapavir
Gilead, a leading force in HIV treatment innovation, dedicated two decades to the progress of lenacapavir. This novel antiviral operates by targeting a crucial protein located on the exterior of the HIV virus. This approach mirrors the mechanism of many vaccines, which function
Worth a look